Glioblastoma or Malignant Glioma — Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma
Citation(s)
Phase 1/1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 as Monotherapy and in Combination With AMG 404 in Subjects With Glioblastoma or Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)